GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
19 January, 2011
Online Tuition Videos Give Rapid Insight into Many Chromatography Procedures
14 January, 2011
CANCER RESEARCH UK’s drug development office (DDO) has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.The move will increase patient access to trials of potential new cancer treatments that combine molecularly targeted experimental drugs developed and owned by AstraZeneca. The trials will also test these combinations alongside conventional chemotherapy radiotherapy and other novel agents.
14 January, 2011